Article

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer

2024-03-03

Abstract excerpt

Mammalian switch/sucrose non-fermentable (mSWI/SNF) ATPase degraders have been shown to be effective in enhancer-driven cancers by functioning to impede oncogenic transcription factor chromatin accessibility. Here, we developed AU-24118, a first-in-class, orally bioavailable proteolysis targeting chimera (PROTAC) degrader of mSWI/SNF ATPases (SMARCA2 and SMARCA4) and PBRM1. AU-24118 demonstrated tumor regression i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5f99d666-2c23-51eb-8ec4-10d37d62a961
DOI: 10.1101/2024.02.29.582768

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerDOI 10.1101/2024.02.29.582768Read

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancerSemantic proximity Read

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivoSemantic proximity Read

Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapySemantic proximity Read

Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer.Semantic proximity Read

Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor DegradationSemantic proximity Read

PROTACs in the Management of Prostate Cancer.Semantic proximity Read

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.Semantic proximity Read

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C InhibitorsSemantic proximity Read

Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.Semantic proximity Read

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancersSemantic proximity Read

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.Semantic proximity Read